Scarica l'app Stockscreener
16.00
6.38%
0.9611
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$15.04
Aprire:
$15.21
Volume 24 ore:
1.27M
Relative Volume:
1.30
Capitalizzazione di mercato:
$2.25B
Reddito:
$340.81M
Utile/perdita netta:
$-419.65M
Rapporto P/E:
-5.6144
EPS:
-2.85
Flusso di cassa netto:
$-402.10M
1 W Prestazione:
-1.84%
1M Prestazione:
-23.15%
6M Prestazione:
-42.78%
1 anno Prestazione:
-22.97%
Intervallo 1D:
$15.10
$16.28
Intervallo di 1 settimana:
$14.20
$16.97
Portata 52W:
$14.20
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8548
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Confronta DNLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
16.02 | 2.25B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
494.74 | 125.50B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.04 | 75.31B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.55 | 35.72B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.40 | 31.39B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.93 | 26.27B | 3.32B | -860.46M | -1.04B | -8.32 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World
Why Denali Therapeutics Shares Are Tumbling - TipRanks
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World
How the (DNLI) price action is used to our Advantage - Stock Traders Daily
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Denali's ALS programme suffers another setback - pharmaphorum
What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World
B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks
Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks
DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - Marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World
DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey
Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating - Marketscreener.com
Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating - Marketscreener.com
Denali Therapeutics: Why Analysts Remain Optimistic - TipRanks
Denali Therapeutics’ (DNLI) “Outperform” Rating Reiterated at William Blair - Defense World
What is HC Wainwright’s Forecast for DNLI Q1 Earnings? - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00 - Defense World
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus - MSN
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In - Insider Monkey
Y Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
William Blair Reiterates "Outperform" Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing - MSN
Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Wedbush Adjusts Price Target on Denali Therapeutics to $32 From $33, Maintains Outperform Rating - Marketscreener.com
Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating - TipRanks
Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating - TipRanks
Denali Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Denali Therapeutics reports Q4 EPS (67c), consensus (85c) - TipRanks
Denali Therapeutics Files For Mixed Shelf Size Not DisclosedSEC Filing -February 27, 2025 at 05:14 pm EST - Marketscreener.com
Denali Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Denali Therapeutics Signs New Equity Distribution Deal - TipRanks
Denali Therapeutics Inc. SEC 10-K Report - TradingView
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Can Denali's Hunter Syndrome Drug Breakthrough Offset $422M Annual Loss? - StockTitan
Trading (DNLI) With Integrated Risk Controls - Stock Traders Daily
Denali Therapeutics (DNLI) to Release Earnings on Tuesday - Defense World
Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Baillie Gifford & Co. Sells 1,031,956 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Tuesday - MarketBeat
Mucopolysaccharidosis Market Analysis Across 7MM — Unveiling Growth Opportunities Across Different Types | DelveInsight - GlobeNewswire Inc.
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):